Skip to content
10-Q

Quarterly Report

MYRIAD GENETICS INC MYGN

0000899923-26-000038

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 94.45M sh
Shares Diluted Q1 2026 · Mar 31, 2026 93.7M sh
Shares Diluted Q1 2026 · Mar 31, 2025 91.4M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$15.7M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$16.3M
Long Term Debt Q1 2026 · Mar 31, 2026 $120.3M
Long Term Debt Q1 2026 · Dec 31, 2025 $119.9M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $124.4M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $149.6M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $91.8M
Stockholders Equity Q1 2026 · Mar 31, 2026 $337.4M
Stockholders Equity Q1 2026 · Dec 31, 2025 $368M
Stockholders Equity Q1 2026 · Mar 31, 2025 $704.9M
Stockholders Equity Q1 2026 · Dec 31, 2024 $701.1M
Current Liabilities Q1 2026 · Mar 31, 2026 $130.2M
Current Liabilities Q1 2026 · Dec 31, 2025 $133.8M
Total Liabilities Q1 2026 · Mar 31, 2026 $336.3M
Total Liabilities Q1 2026 · Dec 31, 2025 $338.6M
Current Assets Q1 2026 · Mar 31, 2026 $312.8M
Current Assets Q1 2026 · Dec 31, 2025 $332.6M
Total Assets Q1 2026 · Mar 31, 2026 $673.7M
Total Assets Q1 2026 · Dec 31, 2025 $706.6M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.36
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 −$0.36
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Rd Expense Q1 2026 · Mar 31, 2026 $27.1M
Rd Expense Q1 2026 · Mar 31, 2025 $27.5M
Net Income Q1 2026 · Mar 31, 2026 −$34.1M
Net Income Q1 2026 · Mar 31, 2025 −$100K
Operating Income Q1 2026 · Mar 31, 2026 −$30.7M
Operating Income Q1 2026 · Mar 31, 2025 −$29M
Gross Profit Q1 2026 · Mar 31, 2026 $137.6M
Gross Profit Q1 2026 · Mar 31, 2025 $134.2M
Revenue Q1 2026 · Mar 31, 2026 $200.4M
Revenue Q1 2026 · Mar 31, 2025 $195.9M